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Abstract: Recent advances in the field of nanotechnology such as nanoencapsulation offer new
biomedical applications, potentially increasing the scope and efficacy of therapeutic drug delivery. In
addition, the discovery and development of novel biocompatible polymers increases the versatility
of these encapsulating nanostructures, enabling chemical properties of the cargo and vehicle to be
adapted to specific physiological requirements. Here, we evaluate the capacity of various polymeric
nanostructures to encapsulate various antibiotics of different classes, with differing chemical structure.
Polymers were sourced from two separate derivatives of poly(methyl vinyl ether-alt-maleic anhydride)
(PMVE/MA): an acid (PMVE/MA-Ac) and a monoethyl ester (PMVE/MA-Es). Nanoencapsulation
of antibiotics was attempted through electrospinning, and nanoparticle synthesis through solvent
displacement, for both polymers. Solvent incompatibilities prevented the nanoencapsulation of
amikacin, neomycin and ciprofloxacin in PMVE/MA-Es nanofibers. However, all compounds
were successfully loaded into PMVE/MA-Es nanoparticles. Encapsulation efficiencies in nanofibers
reached approximately 100% in all compatible systems; however, efficiencies varied substantially in
nanoparticles systems, depending on the tested compound (14%–69%). Finally, it was confirmed that
both these encapsulation processes did not alter the antimicrobial activity of any tested antibiotic
against Staphylococcus aureus and Escherichia coli, supporting the viability of these approaches for
nanoscale delivery of antibiotics.
Keywords: biomaterials; polymers; PMVE/MA; electrospinning; nanofibers; nanoparticles;
nanoencapsulation; antibiotics
1. Introduction
So far, antibiotics are the most reliable weapon against infectious diseases of bacterial origin.
However, the dramatic diminishment in the rate of discovery of new antibiotics limits our response
to pathogens resistant to conventional antibiotics and to new emerging diseases. In response, the
scientific community is developing alternative strategies to increase the effectiveness, and/or to
overcome the limitations, of existing antibiotics [1,2]. In this context, recent advances in the field of
nanotechnology offer new tools such as nanoencapsulation: the loading of pharmaceutical agents
within nanomaterials [3,4].
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From a commercial and clinical point of view, nanoencapsulation can protect pharmaceutical
products, extending both shelf-life and biological half-life (e.g., in circulation). In addition, with the
corresponding modifications, these nanostructured systems can facilitate targeted drug delivery and/or
specific controlled-release kinetics, thereby increasing the effectiveness of the treatment and, thus,
reducing necessary dosage and side effects [3,4].
In line with this, the continuing development of novel biocompatible polymers contributes to the
potential versatility of these nanostructures, by enabling the delivery of compounds with solubility
limitations. In addition, manipulation of synthesis or layering protocols can generate nanostructures
with properties tailored to highly specific applications, for example injectable nanoparticles, or
nanofibers for wound dressings [5–8].
Examples of such highly versatile materials include derivates of poly(methyl vinyl ether-alt-maleic
anhydride) (PMVE/MA), an alternating copolymer of methyl-ether-vinyl and maleic anhydride. This
material is marketed by Ashland Inc. as Gantrez® and presents suitable properties for biomedical
applications (low toxicity, high biocompatibility, high mucoadhesivity and low cost). In particular, it is
reported that PMVE/MA can be structured as loadable nanoparticles [9] and its derivates poly(methyl
vinyl ether-alt-maleic acid) (PMVE/MA-Ac) and poly(methyl vinyl ether-alt-maleic monoethyl ester)
(PMVE/MA-Es) as nanofibers [10,11]. In addition, these polymers have shown utility as matrix elements,
allowing the combination with other materials to generate novel mixtures of chemical properties
in the final nanostructures [11–13], such as with homemade fluorescent cationic fluorene-based
polyelectrolytes [11,14–16].
In this work, both nanoparticles and nanofibers were synthesized using these polymers, and
their relative capacities for encapsulation were compared. There are several possible procedures
for the synthesis of each of these nanomaterials. For instance, solvent displacement, emulsion
solvent diffusion, interfacial deposition and nanoprecipitation synthesis for nanoparticles [17] and
electrospinning, self-assembly, phase separation and template synthesis for nanofibers [18]. The two
nanostructuring methodologies utilized here (solvent displacement and electrospinning, for particle
and fiber synthesis, respectively), although differing markedly in terms of the processes involved,
were selected because of the high degree of uniformity in their products, as well as being scalable
processes for industrial production. The range of compounds tested as cargo encompassed four
antibiotics of three different classes, differing in their molecular weights, structures and modes of action,
i.e., two aminoglycosides (amikacin and neomycin), a cephalosporin (cefotaxime) and a quinolone
(ciprofloxacin). Finally, the antimicrobial activity of the encapsulated compounds, as well as their
structural stability, were also assessed, to confirm that nanoencapsulation was not an impairment to
their antimicrobial potency.
2. Materials and Methods
2.1. Materials
The polymers PMVE/MA-Es (CAS number: 25087-06-3; MW: 130 kg/mol), provided as 50% w/w
solution in ethanol, and PMVE/MA-Ac (CAS number: 25153-40-6; MW: 216 kg/mol), in powder format,
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Amikacin (Mw: 585.6 g/mol; 250 mg/mL)
and cefotaxime (MW: 455.5 g/mol; powder) were acquired from Laboratorios Normon (Tres Cantos,
Spain). Neomycin (MW: 614.6 g/mol; 10 mg/mL) was obtained from Sigma-Aldrich and ciprofloxacin
(MW: 331.3 g/mol; 2 mg/mL) from Genéricos Españoles laboratorios S.A. (Las Rozas, Spain). The
chemical structure inputs of all these compounds are shown in Figure 1.
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Phosphate buffered saline (PBS; pH 7.4), Mueller-Hinton broth (MHB; powder format), methanol,
acetone, phosphoric acid and trifluoroacetic acid with HPLC grade purity, and dimethylsulfoxide
(DMSO) and ethanol with purity >95%, were all from Sigma-Aldrich. The water used was double
distilled and deioniz (DDW) from a Milli-Q Synthesi A10 system (Millipor , Madrid, Sp i ).
2.2. Preparation of Nanofibers by Electrospinning
From our previous studies, eith r 20% w/w PMVE/MA-Ac in H2O or 25% w/w PMVE/MA-Es in
ethanol we e s lected as optimal polymeric solutions for the creatio of electrospun nanofibers [10,11].
Antibiotics were added to the polymeric solutions to reach a final concentration of 1% w/w with resp ct
to bot PMVE/MA-Ac and PMVE/MA-Es. All solutions were stirred for 1 h a d then bath-so icated
for 10 min prior to electrospinning.
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As for the electrospinning system, the polymer solutions inside a 2-mL Discardit II syringe (Becton
Dickinson, Franklin Lakes, NJ, USA) were pumped through a 20-Gauge blunt-end stainless steel
hypodermic needle 316 (Sigma-Aldrich) at a constant flow rate by using a KDS 100 infusion pump
(KD Scientific, Holliston, MA, USA). A Series FC high voltage supplier (Glassman High Voltage Inc.,
Whitehouse Station, NJ, USA) was responsible for the generation of the electrostatic field, which
focused the jet onto a collector, made of aluminum foil and located in front of the syringe tip (vertical
orientation). Any surface intended to be covered with a mat of electrospun nanofibers would be
placed on the collector, for instance common glass slides for fluorescence/optical microscopy analysis
or copper grids (diameter 3 mm) for transmission electron microscopy (TEM; Electron Microscopy
Sciences, Hatfield, PA, USA). Operational parameters: 15 kV, flow rate 0.5 mL/h, needle-collector
distance 15 cm, room temperature (RT) and relative humidity 40%–60%. Finally, in order to evaporate
solvent excess, the obtained mats were kept in a fume hood overnight. Synthesized nanofibers were
then stored protected from light at RT and dry atmosphere until used.
2.3. Preparation of Nanoparticles by Solvent Displacement
The PMVE/MA-Es nanoparticles were created using the solvent displacement procedure previously
described by Arbós et al. (2002) [19] with some modifications. Briefly, different amounts of
PMVE/MA-Es (12.5–200 mg) were dissolved in up to 5 g of ethanol by means of magnetic agitation
for 10 min at RT. Subsequently, 2 µg of antibiotic in DDW were added (control nanoparticles were
prepared only with DDW). After 10 min further magnetic stirring, gradual addition of DDW brought
the final volume to 15 g. Then, the ethanol was evaporated under reduced pressure (BUCHI Rotavapor
R-230, Flawil, Switzerland). Finally, obtained nanoparticles were purified twice by centrifugation
(Sigma 3K30, Sigma Instruments, Osterode, Germany) at 20,000 g for 20 min at 4 ◦C. The pellet was
then resuspended in up to 10 g of DDW and thus the final concentrations were 0.125%–2% w/w (or
1.25–20 mg/g) of PMVE/MA-Es and 200 ng/g of antibiotic. The supernatants were further centrifuged
at 30,000 g for 30 min at 4 ◦C and collected again to quantify the amount of unloaded antibiotics. The
purified nanoparticles and supernatants from all batches were stored at −20 ◦C until use.
2.4. Average Size and Zeta Potential Determination of Nanoparticles
Photon correlation spectroscopy (PCS), also known as dynamic light scattering (DLS), was used
to determine the average hydrodynamic diameter (HDD) and polydispersity index (PDI) of each
batch of nanoparticles (90 Plus Nanoparticle Size Analyzer; 35 mV red diode laser source,
Nanomaterials 2019, 9, x FOR PEER REVIEW 4 of 13 
 
syringe tip (vertical orientation). Any surface intended to be covered with a mat of electrospun 
nanofibers would be placed on the collector, for instance common glass slides for 
fluorescence/optical microscopy analysis or copper grids (diameter 3 mm) for transmission electron 
microscopy (TEM; Electron Microscopy Sciences, Hatfield, PA, USA). Operational parameters: 15 
kV, flow rate 0.5 mL/h, needle-collector distance 15 cm, room temperature (RT) and relative 
humidity 40%–60%. Finally, in order to evaporate solvent excess, the obtained mats were kept in a 
fume hood overnight. Synthesized nanofibers were then stored protected from light at RT and dry 
atmosphere until used. 
2.3. Preparation of Nanoparticles by Solvent Displacement 
The PMVE/MA-Es nanoparticles were created using the solvent displacement procedure 
previously described by Arbós et al. (2002) [19] with some modifications. Briefly, different amounts 
of PMVE/MA-Es (12.5–200 mg) were dissolved in up to 5 g of ethanol by means of magnetic 
agitation for 10 min at RT. Subsequently, 2 µg of antibiotic in DDW were added (control 
nanoparticles were prepared only with DDW). After 10 min further magnetic stirring, gradual 
addition of DDW brought the final volume to 15 g. Then, the ethanol was evaporated under reduced 
pressure (BUCHI Rotavapor R-230, Flawil, Switzerland). Finally, obtained nanoparticles were 
purified twice by centrifugation (Sigma 3K30, Sigma Instruments, Osterode, Germany) at 20,000 g 
for 20 min at 4 °C. The pellet was then resuspended in up to 10 g of DDW and thus the final 
concentrations were 0.125%–2% w/w (or 1.25–20 mg/g) of PMVE/MA-Es and 200 ng/g of antibiotic. 
The supernatants were further centrifuged at 30,000 g for 30 min at 4 °C and collected again to 
quantify the amount of unloaded antibiotics. The purified nanoparticles and supernatants from all 
batches were stored at −20 °C until use. 
2.4. Average Size and Zeta Potential Determination of Nanoparticles 
Photon correlation spectroscopy (PCS), also known as dynamic light scattering (DLS), was used 
to determine the average hydrodynamic diameter (HDD) and polydispersity index (PDI) of each 
batch of nanoparticles (90 Plus Nanoparticle Size Analyzer; 35 mV red diode laser source,  = 640 
nm; Brookhaven Instruments Corporations, Holtsville, NY, USA). Each suspension sample was 
diluted with DDW to yield an appropriate scattering intensity of 100–400 kcps. All measurements 
were performed three times at 25 °C with angle detection fixed at 90° on 2 mL samples. 
The zeta potential (ZP) of the synthesized nanoparticles was determined by electrophoretic 
laser Doppler anemometry with the 90 Plus Particle Size Analyzer (Brookhaven Instruments 
Corporation). Suspension samples were prepared as described before and analyzed in triplicate. All 
results are shown as the mean and standard deviation (s.d.) of the values obtained from three 
different batches.  
2.5. Microscopy 
For optical microscopy initial screenings, the nanofibers were electrospun on microscope slides 
(Deltalab, Barcelona, Spain) and observed by means of a Mycrosystems DMI3000B inverted 
fluorescence microscope equipped with an EL6000 compact light source and a DFC 3000G digital 
camera, all from Leica (Bensheim, Germany). All images were taken with a 63× objective in phase 
= 640 nm;
Brookhaven Instruments Corporations, Holtsville, NY, USA). Each suspension sample was dilut d with
DDW to yield an appropriate scattering intensity of 100–400 kcps. All measurements were performed
three times at 25 ◦C with angle detection fixed at 90◦ on 2 mL samples.
The zeta potential (ZP) of the synthesized nanoparticles was determined by electrophoretic laser
Doppler anemometry with the 90 Plus Particle Size Analyzer (Brookhaven Instruments Corporation).
Suspension samples were prepared as described before and analyzed in triplicate. All results are
shown as the mean and standard deviation (s.d.) of the values obtained from three different batches.
2.5. Microscopy
For optical microscopy initial screenings, the nanofibers were electrospun on microscope slides
(Deltalab, Barcelona, Spain) and observed by means of a Mycrosystems DMI3000B inverted fluorescence
microscope equipped with an EL6000 compact light source and a DFC 3000G digital camera, all from
Leica (Bensheim, Germany). All images were taken with a 63× objective in phase contrast and image
processing performed manually using the software Leica Application SuiteAF6000 Module Systems.
Detailed observations of selected nanofiber samples were carried out by scanning electron
microscopy (SEM), without metal coating, in a JSM-6360 LV device (Jeol, Tokyo, Japan). For size
analysis, diameter measurements were performed on 100 nanofibers (minimum three micrographs)
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per nanofiber synthesis condition using ImageJ software (National Institutes of Health, NIH, Bethesda,
MD, USA).
Transmission electron microscopy (TEM) was used to confirm the size and describe the morphology
of the synthesized nanoparticles (Jeol 1011 apparatus, at 120 kV). Samples were placed onto
Formvar/carbon 300-Mesh, copper grids (Electron Microscopy Science, Hatfield, PA, USA) and
then incubated with citrate lead solution (0.03% p/v) to generate contrast in images. Diameter
measurements were performed on 50 nanoparticles (minimum three micrographs) per nanoparticle
synthesis condition using ImageJ software (National Institutes of Health).
2.6. HPLC Analysis
The quantitation of antibiotics was performed by HPLC in order to determine their encapsulation
efficiency (EE, percentage of encapsulated compound relative to the theoretically maximum one) in
both nanostructures. For nanoparticles, non-loaded compound, i.e., free in supernatants obtained
during synthesis prior to purification, was quantitated then subtracted from the total added antibiotics
to determine the amount of loaded compound. Nanoparticle supernatants or 0.1% w/w nanofiber
solutions in DDW were filtered through a 0.4 µm PTFE membrane (Chmlab group, Barcelona, Spain)
prior to volume injections (10 µL for amikacin and neomycin, 20 µL for ciprofloxacin and 5 µL
for cefotaxime).
A Merck-Hitachi D-7000 HPLC system (Hitachi Instruments, Tokyo, Japan) equipped with an
Alltech 3300 evaporative light scattering detector (ELSD; Alltech Associates Inc., Lokeren, Belgium)
was used to analyze amikacin and neomycin. Cefotaxime and ciprofloxacin were analyzed by means
of an Agilent LC 214 1100 series HPLC system controlled by ChemStation software and equipped with
a G1311A quaternary pump, a G1329A ALS automated sample injector, a G1316A thermostat column
compartment and a G1316A diode array detector (Agilent Technologies, Inc., Palo Alto, CA, USA).
All methods used were isocratic and their particularities for each antibiotic were as follows. For
amikacin and neomycin, the mobile phase was acetone:DDW with 0.15% v/v TFA at a 1:1 ratio, a flow
rate at 1.0 mL/min. ELSD conditions were nitrogen pressure at 3.5 bar and temperature at 45 ◦C. For
cefotaxime, the mobile phase was methanol:DDW at 30:70 v/v (adjusted to pH 4 with acetic acid), a flow
rate at 0.8 mL/min and detection at 235 nm. For ciprofloxacin, the mobile phase was 0.25 M phosphoric
acid:acetonitrile at 75:25 v/v, a flow rate at 0.8 mL/min and detection at 280 nm. Standard curves
for each antibiotic were generated using the same concentration range (6.25–300 µg/mL). Within this
range, a linear correlation was found between concentration and detected peak area with regression
coefficient values (R2) greater than 0.99 (Figure S1).
2.7. Antibacterial Assays
The antimicrobial activity of the experimental formulations was tested on antibiotic-sensitive
strains of Gram-positive Staphylococcus aureus (CECT 59) and Gram-negative Escherichia coli (CECT
515) obtained from the Spanish Type Culture Collection (Colección Española de Cultivos Tipo, CECT,
Universitat de Valencia, Spain). Prior to each assay, a colony of bacteria previously grown in MHB-agar
plates was isolated and incubated in MHB for 12 h at 37 ◦C to prepare bacteria inocula.
Minimal inhibitory concentration (MIC) was determined by the two-fold broth microdilution
method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [20], with some
modifications. Briefly, two-fold dilutions in MHB of the experimental formulations and the control
antibiotics at twice the final concentration were prepared and 50 µL/well were dispensed in each
column (1 column per concentration) of round-bottom 96-well polystyrene plates (Deltalab S.L., Rubí,
Spain). Then, bacteria suspension, after adjustment to 0.5 McFarland and then further diluted by 1:100
in MHB, was added to all wells (50 µL/well), except for sterile controls. Plates were then incubated
for 24 h at 37 ◦C and finally MIC was defined as the lowest concentration of antibiotic that visibly
inhibited the growth of the bacterium being investigated. All assays were performed in triplicate and
results are shown as the mean and s.d.
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2.8. Data Analysis and Graphics
Data were analyzed and graphs produced using GraphPad Prism v6 and Microsoft Excel software.
Statistical analysis was performed with GraphPad Prism v6.
3. Results
3.1. Electrospinnability of Formulations and Characterization of Obtained Nanofibers
In our previous works [10,11], the optimal conditions for the electrospinning of the polymer
solutions for both of these PMVE/MA derivates were determined, and hence taken as starting points
for the present study (briefly, 15 kV, flow rate of 0.5 mL/h, needle-collector distance of 15 cm and
polymer concentrations of 20% w/w PMVE/MA-Ac in H2O or 25% w/w PMVE/MA-Es in ethanol). In this
study, such conditions proved suitable for generating morphologically uniform nanofibers when initial
polymeric solutions were homogenous. However, amikacin, neomycin and ciprofloxacin were found
to be insoluble in ethanol, and therefore insoluble in PMVE/MA-Es solutions. Therefore, nanofibers
were obtained from PMVE/MA-Ac solutions in combination with all antibiotics, but PMVE/MA-Es
solution was only used with cefotaxime.
From both optical microscopy (data not shown) and SEM images (Figure 2), the morphology of
all nanofibers was observed to be uniform (no shape anomalies), continuous (appropriate length, no
breaks) and with a smooth surface appearance (no visible pores).
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As SEM offers higher resolution and contrast imaging, as well as broader depth of field, these 
images were used for size analysis (Figure 2). All nanofiber types showed average diameter values < 
1000  nm,  except  PMVE/MA‐Es/cefotaxime  (1414  ±  200  nm).  PMVE/MA‐Ac  nanofibers  with  no 
encapsulated compound were the narrowest in diameter (126 ± 28 nm), which contrasts starkly with 
non‐loaded PMVE/MA‐Es  fibers  (871  ±  159 nm). The  encapsulation of  compounds  increased  the 
diameter  of  both  PMVE/MA‐Es  and  PMVE/MA‐Ac  nanofibers  by  a  minimum  of  1.6‐fold 
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Figure 2. SEM analysis of antibiotic-loaded electrospun nanofibers. Representative SEM micrographs
and corresponding diameter frequency histograms for PMVE/MA-Ac, PMVE/MA-Ac/amikacin,
PMVE/MA-Ac/neomycin, PMVE/MA-Ac/cefotaxime, PMVE/MA-Ac/ciprofloxacin, PMVE/MA-Es and
PMVE/MA-Es/cefotaxime. Histogram data were obtained from multiple micrographs (100 individual
measurements). Best-fit adjustments (and their R2) to a Gaussian distribution are indicated in blue.
Average diameter (Ø) ± s.d. is also stated. Scale bar: 5 µm.
As SEM offers higher resolution and contrast imaging, as well as broader depth of field, these images
were used for size analysis (Figure 2). All nan fiber ypes showed average diam ter values < 1000 nm,
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except PMVE/MA-Es/cefotaxime (1414 ± 200 nm). PMVE/MA-Ac nanofibers with no encapsulated
compound were the narrowest in diameter (126 ± 28 nm), which contrasts starkly with non-loaded
PMVE/MA-Es fibers (871 ± 159 nm). The encapsulation of compounds increased the diameter of both
PMVE/MA-Es and PMVE/MA-Ac nanofibers by a minimum of 1.6-fold (PMVE/MA-Es/cefotaxime)
and a maximum of 5.0-fold (PMVE/MA-Ac/amikacin). Among PMVE/MA-Ac nanofibers, the smallest
diameter increase was found when loading neomycin (2.4-fold), then ciprofloxacin (3.5-fold), with
cefotaxime increasing the most (4.5-fold). In terms of size variability, PMVE/MA-Ac/amikacin,
PMVE/MA-Ac/cefotaxime, PMVE/MA-Ac/ciprofloxacin and PMVE/MA-Es/cefotaxime nanofibers most
closely fitted a Gaussian distribution (R2 > 0.95), although all formulations showed R2 values higher
than 0.9. Of note, EEs reached maximum levels (≥97%) with relatively low s.d. (±2%) in all cases.
3.2. Optimization of the Preparation of PMVE/MA-Es Nanoparticles and Their Characterization
The low solubility in ethanol of most of the antibiotics tested, and the low solubility in DDW of
PMVE/MA-Es, severely limited their compatibility for encapsulation in electrospun PMVE/MA-Es
nanofibers. In contrast, encapsulation of these antibiotics in PMVE/MA-Es nanoparticles would appear
feasible, since their preparation by the solvent displacement method requires, initially, both much
lower polymer and ethanol concentrations (32.33% w/w). This method continues with the selective
evaporation of ethanol to reach final nanoparticle suspensions in just DDW.
Preliminarily, the process of preparation of PMVE/MA-Es nanoparticles was optimized. For
this purpose, several concentrations of PMVE/MA-Es were tested, ranging from 0.125% to 2% w/w
(thus, 1.25–20 mg/g) in the final formulation. The physico-chemical parameters analyzed for these
nanoparticles are summarized in Table 1. Overall, within the concentration range tested, greater polymer
concentration was associated with larger nanoparticle diameter. No associations were noted between
polymer concentration and either PDI or ZP parameters. PDI values ranged 0.06-0.20, indicating
suspensions with high quality dispersion in general. In contrast, ZP values were more variable (from
−5 to −35 mV), but only nanoparticles made of 10 and 20 mg/g PMVE/MA-Es displayed values yielding
fairly good physical stability (≥30 mV approximately). Given these results, nanoparticles made of
10 mg/g PMVE/MA-Es were selected for further studies.
Table 1. Physico-chemical characteristics of nanoparticles made with different PMVE/MA-Es concentrations.
Conc. (mg/g) HDD (nm) PDI (a.u.) ZP (mV)
1.25 84 ± 5 0.11 ± 0.04 −26 ± 10
2.5 139 ± 26 0.19 ± 0.03 −5 ± 4
5 106 ± 4 0.10 ± 0.04 −5 ± 6
10 202 ± 11 0.20 ± 0.06 −35 ± 9
20 230 ± 1 0.06 ± 0.01 −32 ± 1
Conc., concentration in the final formulation. a.u., arbitrary units. Results shown as the mean ± s.d. (n = 3).
Such nanoparticle formulations were then analyzed by TEM (Figure 3), which revealed consistent
spherical shapes and, in contrast to PCS results, not only a lower average size (114 ± 24 nm), but also a
less homogeneous population, as can be observed from the frequency histogram of their diameters.
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Figure 3. TE analysis of optimized P VE/ A-Es nanoparticles. Representative TE image and
diameter frequency histogram of PMVE/MA-Es nanoparticles synthesized by the solvent displacement
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3.3. Characterization of PMVE/MA-Es Nanoparticles Loaded with Antibiotics
By following the methodology described above, antibiotic-loaded PMVE/MA-Es nanoparticles
were prepared containing 10 mg/g PMVE/MA-Es and 200 ng/g antibiotic (if 100% EE). The
physico-chemical characteristics and EE displayed by these formulations are summarized in Table 2.
Control (non-loaded) nanoparticles showed similar physico-chemical values as observed before
(previous section), confirming the high reproducibility of the technique. As for loaded nanoparticles,
there were significant compound-dependent variations in these parameters. For instance, both
amikacin- and ciprofloxacin-loading was associated with greater particle size, but only the latter
showed a notably change in ZP value (−16 ± 3 mV). Nanoparticles loaded with cefotaxime showed
lower diameter (156 ± 6 nm) in comparison to control, and only neomycin-loaded particles showed no
substantial differences compared to controls. Regarding their EE, only amikacin showed relatively low
values (14% ± 4%), with the other antibiotics ranging from 40% to 69%.
Table 2. Physico-chemical characteristics and encapsulation efficiency (EE) of PMVE/MA-Es
nanoparticles loaded with antibiotics.
Antibiotic HDD (nm) PDI (a.u.) ZP (mV) EE (%)
None 195 ± 7 0.15 ± 0.04 −38 ± 13 -
Amikacin 253 ± 5 0.17 ± 0.07 −39 ± 2 14 ± 4
Neomycin 209 ± 4 0.20 ± 0.07 −29 ± 7 40 ± 3
Cefotaxi e 156 ± 6 0.29 ± 0.03 31 8 69 ± 7
Ciprofloxacin 256 ± 8 0.17 ± 0.01 16 3 59 ± 8
a.u., arbitrary units. Results shown as the mean and s.d. (n = 3).
3.4. nalysis of the ntibacterial ctivity
e antibacterial activity of encapsulated antibiotics was assessed against Gram-positive (S. aureus)
and Gram-negative (E. coli) bacteria y determining their MIC values and comparing to those obtained
f r the free drug. The MIC values displayed by the encapsulated and free antibiotics were not
significantly different (data not shown). As free compounds, MIC values for amikacin, neomyci ,
ciprofloxacin and cefotaxime were 1.25, 0.31, 2.5 and 0.16 µg/mL against S. aureus and 2.5, 1.25, 0.06
and 0.004 µg/mL against E. coli, respectively.
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4. Discussion
The present work provides evidence of the versatility of polymers for generating nanostructures
adapted to the solubility properties of the compounds of interest, for successful encapsulation of these
compounds. Our previous studies provided the first demonstration of electrospinning procedures
optimized for creating nanofibers of the two PMVE/MA derivates used here [10,11]. These were
used to encapsulate 5-aminolevulinic acid (5-ALA) into nanofibers made of each polymer [11], and
a combination of salicylic acid, methyl salicylate and capsaicin into PMVE/MA-Es nanofibers [10].
Here, we demonstrated the encapsulation of four structurally different molecules (with a common
application: antibiotics) into electrospun nanofibers of either PMVE/MA-Ac or PMVE/MA-Es. All the
antibiotics tested were soluble in water, and thus encapsulate into PMVE/MA-Ac nanofibers, but only
cefotaxime was also soluble in ethanol, and consequently the only one loadable into PMVE/MA-Es
nanofibers. In this regard, as many drugs are hydrophobic, the description of electrospinnable polymers
with properties compatible for encapsulating hydrophobic compounds, is of great importance in
order to incorporate such molecules into electrospun nanofibers while maintaining their biological
functionality. This issue has been revisited by several authors recently [21,22]. Furthermore, these
polymers might also work as a shell phase in both co-axial and layer-by-layer electrospinning in
order to either manipulate the delivery dynamics of high hydrophilic molecules to the particular
requirements or to adapt the delivery system to the needs of the biological context [23,24].
Although the morphology of the nanofibers was not affected by the encapsulation of molecules,
their diameter did undergo considerable changes in comparison to non-loaded fibers. The extent of
these increases in diameter was related to the compound used (1.6-fold for PMVE/MA-Es/cefotaxime
nanofibers and 2.4–5.0-fold for loaded PMVE/MA-Ac nanofibers). These increases were larger than
expected, as only 1% w/w antibiotic was used in all cases and loading percentages for relatively similar
compounds are usually much higher with no, or even reduced, diameter [10,25,26]. In general, within
moderate encapsulation levels, the diameter of electrospun nanofibers commonly increases with
viscosity and decreases with conductivity [25–29], and since the compounds used here are not salts or
polyelectrolytes, they might be increasing the viscosity of the electrospinnable solution [25,26]. In any
case, the current study employs the same synthesis parameters for all formulations in order to reliably
determine any possible morphological or size changes between the different antibiotics incorporated,
and if it is desirable to strictly limit any increase in size, it might be achievable by optimizing such
parameters for each particular formulation, as shown in our previous studies [10,11].
This work has shown the flexibility of nanostructuration of some polymers and offers
alternative encapsulating nanomaterials for compounds whose solubility limitations hinder their
biological/therapeutic applications. Although amikacin, neomycin and ciprofloxacin could not be
loaded into PMVE/MA-Es nanofibers by electrospinning, the solubility of all integrating molecules
with water:ethanol solutions allowed their encapsulation into PMVE/MA-Es nanoparticles, synthesized
by the solvent displacement method. This methodology has been widely reported to create PMVE/MA
nanoparticles for drug delivery purposes because of the interesting mucoadhesive properties of this
polymer [19,30]; however, to our knowledge, there are no publications describing nanoparticles made
of PMVE/MA-Es apart from the patent with reference number US20140161892A1 [31].
The optimized methodology for encapsulating particles (10 mg/g PMVE/MA-Es) produced
polymeric nanoparticles with size (200 nm), PDI (0.2) and ZP (−35 mV). Briefly, at the concentrations
tested, the greater the polymer concentration used, the larger the nanoparticle diameter produced,
while formulations with smaller nanoparticles showed less adequate PDI and ZP values than the
selected one. The PDI, which ranges from 0 to 1, reflects the width of the particle size distribution
and values lower than 0.3 are commonly considered as optimum [32]. Regarding the ZP, which
reflects the level of surface electrostatic potential, values of approximately −30 mV are associated with
physical stability and are considered at the limit for colloidal organizations (theoretically, about −60 mV
minimum is considered optimal) [33,34]. Comparing to these results, loaded nanoparticles did not
differ much in the PDI, ZP and size values obtained, which is in accordance with some studies [35–39].
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In contrast, the size of PMVE/MA-Es nanoparticles did change notably (increased by about 25%)
for some antibiotics, although not as dramatically as in loaded PMVE/MA-Ac nanofibers. Interestingly,
the greatest size increases were found when encapsulating amikacin into both types of nanostructures;
however, no further correlations could be established for the remaining antibiotics. These size changes
do not appear to be related to their MWs, nor to their EEs. For instance, despite the two aminoglycosides
tested, amikacin and neomycin, presenting similar MWs (585.6 and 614.6 g/mol, respectively) and
chemical structures (see Figure 1), the size change of their encapsulating nanostructures (625 vs. 304 nm
in nanofibers and 253 vs. 209 nm in nanoparticles) and their EEs (14% vs. 40%) are very different. In
this regard, the scarcity of nanoencapsulation studies for amikacin, neomycin cefotaxime and, to a
lesser extent, ciprofloxacin [40–43], hampers any meaningful assessment or comparison.
Nevertheless, all tested antibiotics, when encapsulated into either nanomaterial, showed similar
antibacterial activity as their free forms, indicating that none of the synthesis methodologies used
substantially modified their chemical structures. This observation encourages the performance of
follow-up experiments focused on assessing any potential advantages conferred by the described
encapsulating nanomaterials in terms of controlled release, targeted delivery or other therapeutic
impact. Any such advantages may help to overcome the drawbacks restricting the clinical use of some
therapeutics (such as toxicity, poor penetration of biological barriers and short circulating half-life) [44].
5. Conclusions
The compatibility in solubility of both the polymer source and the compound of interest is a
critical factor limiting the production of loaded polymeric electrospun nanofibers. However, it has
been demonstrated here that the high versatility with which some polymers can be assembled into
nanomaterials, in this work PMVE/MA-Ac and PMVE/MA-Es, offers novel encapsulating strategies to
overcome such constraints. In this context, it has also been shown that the encapsulation efficiency,
nanostructuration settings and/or the morphology/size of the final nanostructures are highly dependent
upon the chemical properties, rather than the molecular weight, of the compounds to be encapsulated.
In contrast, it is confirmed that none of the nanostructuring procedures employed alters the activity of
a set molecules with different chemical structures.
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